Search results
Results From The WOW.Com Content Network
One of the most notable scientific papers that first popularized hydroxychloroquine as a COVID-19 treatment was retracted from its journal due to ethical and methodological issues. Retractions in ...
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
During April, the British RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was launched initially in 132 hospitals across the UK, [215] expanding to become one of the world's largest COVID-19 clinical studies, involving 5400 infected people under treatment at 165 UK hospitals, as of mid-April. [216]
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
Yujia Alina Chan is a Canadian molecular biologist specializing in gene therapy and cell engineering at the Broad Institute of MIT and Harvard, where she is a postdoctoral fellow. During the COVID-19 pandemic , she became known for supporting the hypothesis that the SARS-CoV-2 virus escaped from a lab , contrary to the prevailing consensus ...
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5]
As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines. [4] Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from ...
It cleaves the coronavirus polyprotein at eleven conserved sites. It is a cysteine protease and a member of the PA clan of proteases. It has a cysteine-histidine catalytic dyad at its active site and cleaves a Gln–(Ser/Ala/Gly) peptide bond. The Enzyme Commission refers to this family as SARS coronavirus main proteinase (M pro; EC 3.4.22.69).